Sandy Wong, MD

Articles

Dr. Wong on Treatment Goals in Systemic Amyloidosis

July 7th 2021

Sandy Wong, MD, discusses treatment goals for patients with systemic amyloidosis.

Latest in Myeloma, Prostate Cancer, and Lymphoma From ASCO 2021: Drs Neal Shore, Loretta Nastoupil, and Sandy Wong

June 9th 2021

OncLive sits down with Sandy Wong, MD; Neal Shore, MD; and Loretta Nastoupil, MD, to share the the insight on data in multiple myeloma, prostate cancer, and non-Hodgkin lymphoma at the 2021 ASCO Annual Meeting.

Dr. Wong on Recent Developments in AL Amyloidosis

September 10th 2020

Sandy Wong, MD, highlights recent developments in light chain amyloidosis.

Dr. Wong on the Potential Role of Venetoclax in Relapsed/Refractory AL Amyloidosis

August 18th 2020

Sandy Wong, MD, discusses the potential role of venetoclax in relapsed/refractory light chain amyloidosis.

Dr. Wong on Antibody-Drug Conjugate Research in Multiple Myeloma

January 23rd 2020

Sandy Wong, MD, discusses the ongoing research of antibody-drug conjugates in multiple myeloma.

Dr. Wong on Mitigating Toxicities of Selinexor in R/R Multiple Myeloma

January 18th 2020

Sandy Wong, MD, discusses ways to mitigate the toxicities of selinexor in patients with relapsed/refractory multiple myeloma.

Dr. Wong on Investigational CAR T-Cell Products in Multiple Myeloma

January 3rd 2020

Sandy Wong, MD, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.

Dr. Wong on an Investigational Antibody-Drug Conjugate in Multiple Myeloma

January 18th 2019

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses an investigational antibody-drug conjugate (ADC) in multiple myeloma.

Dr. Wong Discusses the FDA Approval of Elotuzumab Triplet in Myeloma

November 7th 2018

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses the FDA approval of elotuzumab (Empliciti) for use in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Wong on a Trial With an Anti-CD46 Antibody in Myeloma

October 10th 2018

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses a trial with an anti-CD46 antibody in multiple myeloma.

Dr. Wong on Anti-Amyloid Fibril Treatments in AL Amyloidosis

February 6th 2018

Sandy Wong, MD, assistant professor, University of California, San Francisco School of Medicine, discusses anti-amyloid fibril treatments, a class of agents that have yet to receive FDA approval in the treatment of patients with immunoglobulin light chain amyloidosis (AL amyloidosis).

Dr. Wong on the Difficulty of Diagnosing Patients With AL Amyloidosis

January 27th 2018

Sandy Wong, MD, assistant professor, University of California, San Francisco School of Medicine, discusses the presentation of AL amyloidosis in patients.

Dr. Wong Discusses Monoclonal Antibodies in Plasma Cell Neoplasms

October 11th 2017

Sandy Wong, MD, assistant professor, Division of Hematology/Oncology, UCSF School of Medicine, discusses monoclonal antibodies in plasma cell neoplasms.